Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.3102
-0.0298-8.76%
Post-market: 0.31480.0046+1.48%19:18 EDT
Volume:1.10M
Turnover:357.05K
Market Cap:5.86M
PE:-0.08
High:0.3401
Open:0.3371
Low:0.3058
Close:0.3400
52wk High:14.80
52wk Low:0.3058
Shares:18.90M
Float Shares:17.23M
Volume Ratio:0.74
T/O Rate:6.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.18
PE(LYR):-0.07

Loading ...

VolitionRx effects 1-for-20 reverse stock split April 28

Reuters
·
Apr 18

VolitionRX Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 03

VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright

TIPRANKS
·
Apr 03

VolitionRx shareholders approved reverse stock split authorization at special meeting

Reuters
·
Apr 02

VolitionRx publishes corporate presentation outlining Nu.Q licensing-led cancer and sepsis diagnostics strategy

Reuters
·
Apr 01

VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate

Benzinga Earnings
·
Apr 01

VolitionRx FY25 net loss narrows 14%; revenue rises 40% to $1.7 million

Reuters
·
Apr 01

Press Release: VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Dow Jones
·
Apr 01

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 31

VolitionRX Ltd - Secures €2.0 Mln Non-Dilutive Funding From Belgian Regional Agencies

THOMSON REUTERS
·
Mar 31

Press Release: VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Dow Jones
·
Mar 31

VolitionRx study shows Nu.Q nucleosome biomarkers elevated in trauma patients, linked to VTE

Reuters
·
Mar 30

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 27

VolitionRx announces ELCC abstract on Nu.Q lung cancer blood test; study links preoperative H3K27Me3-nucleosome levels to recurrence-free and overall survival risk stratification

Reuters
·
Mar 26

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

THOMSON REUTERS
·
Mar 26

VolitionRx schedules FY2025 earnings conference call; business update webcast opens to investors

Reuters
·
Mar 26

VolitionRx reports Capture-Seq blinded validation sensitivity rises to 93%; specificity climbs to 95%

Reuters
·
Mar 25

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 19

BRIEF-Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna

Reuters
·
Mar 18

VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives

Reuters
·
Mar 18